Indaptus Therapeutics (INDP) News Today $0.94 +0.02 (+1.63%) Closing price 01/30/2025 03:49 PM EasternExtended Trading$0.90 -0.04 (-4.28%) As of 01/30/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq RulesJanuary 13, 2025 | stockhouse.comIndaptus Therapeutics looks to raise $2.25M in private placementJanuary 13, 2025 | msn.comIndaptus Therapeutics announces anticipated milestones in 1H of 2025January 8, 2025 | markets.businessinsider.comIndaptus Therapeutics Provides Year-End Review and Outlook for 2025January 8, 2025 | globenewswire.comIndaptus Therapeutics files to sell 1.94M shares of common stock for holdersDecember 23, 2024 | markets.businessinsider.comIndaptus Therapeutics files to sell 1.94M shares of common stockDecember 23, 2024 | msn.comIndaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private PlacementNovember 22, 2024 | globenewswire.comIndaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | markets.businessinsider.comIndaptus Therapeutics price target lowered to $5 from $8 at MaximNovember 13, 2024 | markets.businessinsider.comIndaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in ImmunologyNovember 11, 2024 | globenewswire.comIndaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual MeetingNovember 7, 2024 | globenewswire.comIndaptus Therapeutics to Present at Two Upcoming Investor ConferencesOctober 23, 2024 | globenewswire.comIndaptus Therapeutics Shares Rise After Pact to Develop Cancer TreatmentOctober 22, 2024 | marketwatch.comIndaptus Therapeutics announces clinical supply agreement with BeiGeneOctober 22, 2024 | markets.businessinsider.comIndaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer ImmunotherapyOctober 10, 2024 | markets.businessinsider.comIndaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitOctober 8, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comIndaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 12, 2024 | markets.businessinsider.comInsider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2mAugust 11, 2024 | finance.yahoo.comIndaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private PlacementAugust 8, 2024 | markets.businessinsider.comIndaptus stock dips on $3M securities offeringAugust 8, 2024 | msn.comIndaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual MeetingMay 29, 2024 | finance.yahoo.comIndaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsMay 22, 2024 | finance.yahoo.comINDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024May 8, 2024 | investorplace.comIndaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comBuy Rating Affirmed for Indaptus Therapeutics Amidst Promising Clinical Advances and Potential Market ImpactApril 16, 2024 | markets.businessinsider.comIndaptus reveals immune-boosting cancer therapy dataApril 12, 2024 | investing.comBuy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough with Decoy20 PlatformApril 12, 2024 | markets.businessinsider.comIndaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingApril 11, 2024 | globenewswire.comArmaguard rebuffs $26m cash lifelineMarch 28, 2024 | msn.comIndaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 28, 2024 | finance.yahoo.comIndaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingMarch 25, 2024 | globenewswire.comIndaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024March 18, 2024 | finance.yahoo.comIndaptus Dives on Quarterly ResultsMarch 13, 2024 | msn.comIndaptus Therapeutics: Q4 Earnings InsightsMarch 13, 2024 | benzinga.comIndaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | globenewswire.comIndaptus Reports Positive Decoy20 Results, To Advance To Multi-dosing; Stock Up In Pre-marketMarch 4, 2024 | markets.businessinsider.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Stock (NASDAQ:INDP) Insider TradesFebruary 25, 2024 | benzinga.comIndaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 15, 2024 | finance.yahoo.comIndaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsFebruary 8, 2024 | finance.yahoo.comEuropean Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyJanuary 4, 2024 | finance.yahoo.comIndaptus Therapeutics, Inc. (INDP) stock forecast and price targetDecember 22, 2023 | finance.yahoo.comIndaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20November 27, 2023 | msn.comAnalysts Conflicted on These Healthcare Names: Ventyx Biosciences (VTYX) and Indaptus Therapeutics (INDP)November 7, 2023 | markets.businessinsider.comIndaptus Therapeutics GAAP EPS of -$0.47 beats by $0.05November 6, 2023 | msn.comIndaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 6, 2023 | finance.yahoo.comIndaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 StudyNovember 6, 2023 | finance.yahoo.comIndaptus Therapeutics: Promising Phase 1 Results and Optimistic Valuation Bolster Buy RatingNovember 4, 2023 | markets.businessinsider.com Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address INDP Media Mentions By Week INDP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INDP News Sentiment▼1.430.72▲Average Medical News Sentiment INDP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INDP Articles This Week▼20▲INDP Articles Average Week Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OKYO News OCX News INKT News IXHL News KALA News LEXX News AKTX News LSTA News CVKD News VRCA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INDP) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDP Stock Alerts